Clinical Trials Browser

Interventional × toripalimab × Lymphoid × Clear all

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Phase 3 Recruiting

Hodgkin Disease

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Phase 1 Recruiting

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT04058470 2022-04-14

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03316144 2020-09-30

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Phase 1 Completed

Lymphoma

NCT02836834 2019-10-22

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Phase 1 Unknown

LymphoidThoracic

Lung Neoplasms, Lymphoma